Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
出版年份 2019 全文链接
标题
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I
作者
关键词
-
出版物
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
出版商
Oxford University Press (OUP)
发表日期
2019-07-24
DOI
10.1093/jac/dkz347
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population
- (2018) Soo-Yon Rhee et al. CLINICAL INFECTIOUS DISEASES
- Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial
- (2018) Jose L Blanco et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Epidemiology of HIV drug resistance in HIV patients with virologic failure of first-line therapy in the country of Georgia
- (2018) Ekaterine Karkashadze et al. JOURNAL OF MEDICAL VIROLOGY
- Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
- (2018) Jean-Michel Molina et al. Lancet HIV
- Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial
- (2018) Eric S Daar et al. Lancet HIV
- Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study
- (2018) Chien-Yu Cheng et al. Infection and Drug Resistance
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
- (2018) Michael S. Saag et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults
- (2017) Joel E. Gallant et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide
- (2017) Nicolas A. Margot et al. JOURNAL OF INFECTIOUS DISEASES
- Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial
- (2017) Paul E Sax et al. LANCET
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
- (2017) Joel Gallant et al. LANCET
- Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
- (2017) Ingeborg Wijting et al. Lancet HIV
- Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants
- (2016) M. Noguera-Julian et al. CLINICAL MICROBIOLOGY AND INFECTION
- Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia
- (2016) C. Katlama et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Deep Sequencing of HIV-1 RNA and DNA in Newly Diagnosed Patients with Baseline Drug Resistance Showed No Indications for Hidden Resistance and Is Biased by Strong Interference of Hypermutation
- (2016) Kenny Dauwe et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Reduced Viral Fitness and Lack of Cross-Class Resistance with Integrase Strand Transfer Inhibitor and Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations
- (2015) Kristen N. Andreatta et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions
- (2015) Kristen N. Andreatta et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure
- (2013) Ya-Chi Ho et al. CELL
- Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003–2010
- (2012) Michael D Miller et al. ANTIVIRAL THERAPY
- APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon
- (2012) Andrew E. Armitage et al. PLoS Genetics
- Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia
- (2011) M. Wirden et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study
- (2011) Linda Wittkop et al. LANCET INFECTIOUS DISEASES
- Prevalence of HIV‐1 Drug Resistance after Failure of a First Highly Active Antiretroviral Therapy Regimen in KwaZulu Natal, South Africa
- (2008) Vincent C. Marconi et al. CLINICAL INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started